Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Efpeglenatide

MARKETED

GLP-1 receptor agonist (exendin-4-based)

2
graded findings
2
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 0Very low evidence 0

Efpeglenatide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Efpeglenatide MARKETED
Cardiovascular outcomes Decrease
Moderate evidence

In T2D with CVD or kidney disease plus another risk factor, efpeglenatide reduced MACE versus placebo, with a dose-dependent trend, and reduced a kidney composite. An...

Gerstein HC et al., N Engl J Med, 2021 Source
Full findingIn T2D with CVD or kidney disease plus another risk factor, efpeglenatide reduced MACE versus placebo, with a dose-dependent trend, and reduced a kidney composite. An exendin-4-based agent showing hard CV benefit.
PopulationAMPLITUDE-O: N=4076; T2D with CVD or kidney disease; double-blind placebo-controlled RCT; median 1.8 years.
Fundingindustry - Sanofi (efpeglenatide, AMPLITUDE-O; disclosed)
Scope limitsADDED. Key because efpeglenatide is exendin-4-BASED yet showed clear CV benefit (HR 0.73), countering the idea that exendin-based agents are inert on MACE; it is the trial folded into the Sattar 2021 class meta-analysis. High background SGLT2i use enabled interaction analyses.
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Efpeglenatide MARKETED
renal Decrease
Moderate evidence

AMPLITUDE-O: in T2D with cardiovascular disease or kidney disease plus a risk factor, efpeglenatide reduced a composite renal outcome (decreased kidney function or new...

Gerstein HC et al., N Engl J Med, 2021 Source
Full findingAMPLITUDE-O: in T2D with cardiovascular disease or kidney disease plus a risk factor, efpeglenatide reduced a composite renal outcome (decreased kidney function or new macroalbuminuria) versus placebo (HR 0.68), a prespecified secondary alongside the MACE primary.
PopulationAMPLITUDE-O (NCT03496298): 4076 randomised (2717 efpeglenatide 4/6 mg, 1359 placebo); T2D + CVD or CKD (eGFR 25.0-59.9) + a risk factor; median follow-up 1.81 years; double-blind RCT; SGLT2i-stratified.
Fundingindustry - Sanofi (efpeglenatide, AMPLITUDE-O; disclosed)
Scope limitsNEW-GATHER (identifier already in corpus as MACE-only finding C-EFPE-CARDIO-01; the RENAL composite was missing). Top-tier CVOT renal secondary. Net-new OBSERVATION on an EXISTING source (PMID 34215025, Gerstein NEJM 2021, DOI 10.1056/NEJMoa2108269); inherits the source's grade. Albuminuria-inclusive composite (not a hard kidney-failure-only endpoint). AMPLITUDE-O renal composite HR 0.68 (95% CI 0.57-0.79; P<0.001), 13.0% vs 18.4%, independently re-confirmed via PubMed get_article_metadata 2026-06-24. Independently compendium substance-audited 2026-06-24 (WI-2 audit agent, distinct from the wi2-fold collector); see validation_evidence.
Comparatorsplacebo